arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Sana Biotechnology, Inc.

SANA
$2.32 ▼ -0.24 (-9.38%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
28 Visible periods
18 Metrics
Peer-ranked Benchmarks
Price Chart
16
Health
Poor
Bearish
auto_awesome

Analytical Summary

Sana Biotechnology, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $685.9M
Dividend Yield —
Revenue Growth —
Op. Margin —
ROIC -33.4% ↘
FCF / Share $-0.12 ↗
Trailing P/E —
Price / Book 4.5x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

28-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Net Income Profit after all expenses
$-47.21M
↑ +4.4% —
FCF / Share Free cash flow per share
$-0.12
↑ +14.5% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓
5
Cash Quality ↓
44

bar_chart Data from SEC EDGAR XBRL filings

Synced 5 days ago 8 years · 28 quarters